Literature DB >> 14924173

The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice.

L MALONE, A SCHURR, H LINDH, D McKENZIE, J S KISER, J H WILLIAMS.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID/derivatives; TUBERCULOSIS/experimental

Mesh：

Substances：

Year:  1952        PMID： 14924173

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  23 in total

Review 1.  Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.

Authors:  Sumit Chakraborty; Kyu Y Rhee
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-15       Impact factor: 6.915

Review 2.  Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.

Authors:  Pooja Gopal; Gerhard Grüber; Véronique Dartois; Thomas Dick
Journal:  Trends Pharmacol Sci       Date:  2019-11-06       Impact factor: 14.819

Review 3.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

4.  Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.

Authors:  Helena I Boshoff; Valerie Mizrahi; Clifton E Barry
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

5.  Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis.

Authors:  Karolien Stoffels; Vanessa Mathys; Maryse Fauville-Dufaux; René Wintjens; Pablo Bifani
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

6.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

7.  Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility.

Authors:  S P Klemens; C A Sharpe; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

8.  Use of pyrazinamide (aldinamide) in the treatment of tuberculous lymphadenopathy and draining sinuses; a preliminary report.

Authors:  J W V CORDICE; L M HILL; L T WRIGHT
Journal:  J Natl Med Assoc       Date:  1953-03       Impact factor: 1.798

9.  Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.

Authors:  R J Speirs; J T Welch; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

10.  In vitro antimycobacterial activities of pyrazinamide analogs.

Authors:  S Yamamoto; I Toida; N Watanabe; T Ura
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.